A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?
作者信息
Carlson Sinead, Vaz Karl, Peterson Adam
机构信息
Department of Gastroenterology, Monash Health, School of Clinical Sciences, Monash University, Australia.
Department of Gastroenterology, Alfred Health, Central Clinical School, Monash University, Australia; Department of Gastroenterology, Austin Health, Australia.
出版信息
J Hepatol. 2023 Oct;79(4):e154-e155. doi: 10.1016/j.jhep.2023.01.021. Epub 2023 Feb 1.
PMID:36736735
Abstract
摘要
相似文献
1
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?
J Hepatol. 2023 Oct;79(4):e154-e155. doi: 10.1016/j.jhep.2023.01.021. Epub 2023 Feb 1.
2
Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?'.
J Hepatol. 2023 Oct;79(4):e155-e157. doi: 10.1016/j.jhep.2023.06.005. Epub 2023 Jun 27.
3
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Considerations.
J Hepatol. 2022 Dec;77(6):1722-1724. doi: 10.1016/j.jhep.2022.05.032. Epub 2022 Jun 9.
4
Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma.抗病毒治疗、乙肝表面抗原血清清除及乙肝相关肝细胞癌的晚期复发
J Hepatol. 2022 Nov;77(5):1471-1472. doi: 10.1016/j.jhep.2022.07.005. Epub 2022 Jul 19.
5
Reply to: Correspondence on "Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection".回复：关于“乙肝表面抗原血清学清除对手术切除后乙肝病毒相关肝细胞癌晚期复发的影响”的通信
J Hepatol. 2022 Nov;77(5):1472-1474. doi: 10.1016/j.jhep.2022.07.032. Epub 2022 Aug 18.
6
Letter: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.
Aliment Pharmacol Ther. 2017 May;45(9):1286-1288. doi: 10.1111/apt.13983.
7
Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma.
Aliment Pharmacol Ther. 2016 Jul;44(2):210-1. doi: 10.1111/apt.13674.
8
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.乙型肝炎表面抗原血清学清除后肝细胞癌风险预测模型。
J Hepatol. 2022 Sep;77(3):632-641. doi: 10.1016/j.jhep.2022.03.032. Epub 2022 Apr 7.
9
Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.HBsAg 血清学清除对乙型肝炎病毒相关肝细胞癌切除术后晚期复发的影响。
J Hepatol. 2022 Oct;77(4):939-946. doi: 10.1016/j.jhep.2022.05.014. Epub 2022 May 26.
10
Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.乙肝 e 抗原血清学转换后乙型肝炎表面抗原血清学清除患者的肝细胞癌和长期结局及预测评分。
Hepatology. 2018 Aug;68(2):462-472. doi: 10.1002/hep.29874. Epub 2018 Jun 6.
Zotero 插件